(Related data drawing)
The three major stock index futures have strengthened collectively. As of press release, Nasdaq Futures $NQmain is up 0.56%, S&P 500 Index Futures $ESmain is up 0.38%, and Dow Futures $YMmain is up 0.21%.
In terms of ETF, 1.5 times of daily long Tesla ETF $TSLL rose by more than 7%, 3 times of long FTSE China ETF $YINN rose by more than 4%, and 2 times of long Shanghai and Shenzhen China Internet stock ETF $CWEB rose by more than 3%.
Tesla $TSLA rose more than 5% in the first session. Morgan Stanley upgraded its rating from "flat" to "overweight" and listed it as "preferred stock".
Other US stocks
Popular Chinese concept stocks rose collectively, Baiji Shenzhou rose by 7%, Xiaopeng Auto, Bilibili rose by more than 4%, NetEase rose by more than 3%, Baidu, New Oriental Education, Ideals Auto, Ctrip, Weilai, Shell rose by more than 2%, Pinduoduo, iQiyi, Tencent Music rose by more than 1%, and Alibaba rose slightly.
Big Mo: Thanks to the Dojo supercomputer, Tesla's share price will soar
Morgan Stanley said that the Tesla Dojo supercomputer could enable the company to adopt automated taxis and network services more quickly, increasing the company's market value by up to $500 billion. Dojo can open a "new potential market", just like AWS did for Amazon, analysts such as Adam Jonas and Daniela M Haigian wrote in the report. Morgan Stanley upgraded the stock from neutral to overweight, and raised its 12-month target price from $250 to $400. Tesla's share price has more than doubled this year and closed at $248.50 on Friday.
Baekje China and Green Leaf Pharmaceutical launched the commercialization of BTW
Green Leaf Pharmaceutical's independently developed innovative preparation Goserelin Microspheres for Injection (Chinese trademark: BTV) has been approved by the State Drug Administration of China for use in premenopausal and perimenopausal women with breast cancer who can be treated with hormone. At present, Green Leaf Pharmaceutical and Baiji Shenzhou Co., Ltd. are cooperating to commercialize this product in mainland China.
Disclaimer: The above content only represents the author's personal position and opinion, does not represent any position of Huasheng, nor is it intended to provide any investment advice. The relevant content does not constitute any professional advice, offer, solicitation or suggestion for buying or selling any investment products or services. The content of this page can be modified at any time without further notice. Our company has tried our best to ensure the accuracy and completeness of the data and content above. If you have any questions about the above content, you should consult independent professional opinions. Our company will not bear any responsibility for any loss caused by such information. The above contents have not been reviewed by the SFC.
